Lake Street Maintains Buy on Journey Medical, Raises Price Target to $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $13.
Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $13.